STI Medical Systems, from San Diego, CA., has received FDA clearance for its ImageSense technology for colposcopy. It is an image-subtraction technique for use with the UltraSight digital colposcopy system. Acetic acid is often applied to the cervix during colposcopy after which areas that turn white are considered for biopsy. This technology enhances the visibility of the white areas.
From the press release:
Acetowhitening is one indicator currently used by doctors to identify areas of the cervix possibly containing disease. ImageSense is a tool for displaying areas of acetowhitening by producing a digital output depicting the color differences of the cervix before and after the application of acetic acid during a typical colposcopic exam. By digitizing and memorializing an otherwise transient effect and enabling on-demand viewing of the acetowhite process, ImageSense displays information to the doctor in ways previously not possible.
ImageSense technology is currently in use on the Company’s UltraSightHD™ digital colposcopy system. The combined product offers a fully integrated clinical workflow solution for colposcopy that also incorporates DICOM-compatible imagery and a seamless Electronic Medical Records (EMR) interface via its onboard touch-screen user interface. ImageSense technology provides the UltraSightHD product with a unique competitive advantage over all other colposcopes in the market.
Press release: U.S. Food and Drug Administration (FDA) clears novel ImageSense(tm) technology for use with colposcopy…
Product page: ImageSense…